Ted Wun

Ted Wun

Auto-generated profile, based on publicly available information

Ted Wun

University of California-Davis Cancer Center, Sacramento, California, United States

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Best Practice & Research Clinical Haematology
Verified
Journal Article
Closed access
TWTed Wun
Ted Wun
RWRichard H. White
Richard H. White

21 February 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
JZJeffrey I. Zwicker
Jeffrey I. Zwicker
BSBenjamin L. Schlechter
Benjamin L. Schlechter
JSJack D. Stopa
Jack D. Stopa
HLHoward A. Liebman
Howard A. Liebman
AAAnita Aggarwal
Anita Aggarwal
RFRobert Flaumenhaft
Robert Flaumenhaft
BACKGROUND. Protein disulfide isomerase (PDI) is a thiol isomerase secreted by vascular cells that is required for thrombus formation. Quercetin flavonoids inhibit PDI activity and block platelet accumulation and fibrin generation at the site of a vascular injury in mouse models, but the clinical effect of targeting extracellular PDI in humans has not been studied. METHODS. We conducted a multicenter phase II trial of sequential dosing cohorts to evaluate the efficacy of targeting PDI with isoquercetin to reduce hypercoagulability in cancer patients at high risk for thrombosis. Patients received isoquercetin at 500 mg (cohort A, n = 28) or 1000 mg (cohort B, n = 29) daily for 56 days, with laboratory assays performed at baseline and the end of the study, along with bilateral lower extremity compression ultrasound. The primary efficacy endpoint was a reduction in D-dimer, and the primary clinical endpoint included pulmonary embolism or proximal deep vein thrombosis. RESULTS. The administration of 1000 mg isoquercetin decreased D-dimer plasma concentrations by a median of –21.9% ( P = 0.0002). There were no primary VTE events or major hemorrhages observed in either cohort. Isoquercetin increased PDI inhibitory activity in plasma (37.0% in cohort A, n = 25, P < 0.001; 73.3% in cohort B, n = 22, P < 0.001, respectively). Corroborating the antithrombotic efficacy, we also observed a significant decrease in platelet-dependent thrombin generation (cohort A median decrease –31.1%, P = 0.007; cohort B median decrease –57.2%, P = 0.004) and circulating soluble P selectin at the 1000 mg isoquercetin dose (median decrease –57.9%, P < 0.0001). CONCLUSIONS. Isoquercetin targets extracellular PDI and improves markers of coagulation in advanced cancer patients. TRIAL REGISTRATION. Clinicaltrials.gov NCT02195232. FUNDING. Quercegen Pharmaceuticals; National Heart, Lung, and Blood Institute (NHLBI; U54HL112302, R35HL135775, and T32HL007917); and NHLBI Consortium Linking Oncology and Thrombosis (U01HL143365).

11 January 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
AMAnjlee Mahajan
Anjlee Mahajan
ABAnn Brunson
Ann Brunson
OAOyebimpe Adesina
Oyebimpe Adesina
TKTheresa H.M. Keegan
Theresa H.M. Keegan
TWTed Wun
Ted Wun
Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality for patients with malignancy and varies by primary cancer type, stage, and therapy. We aimed to characterize the incidence, risk factors, temporal trends, and the effect on mortality of CAT. The California Cancer Registry was linked to the statewide hospitalization database to identify individuals with the 13 most common malignancies diagnosed between 2005 and 2017 and determine the 6- and 12-month cumulative incidence of CAT by venous thromboembolism (VTE) location, tumor type, and stage after adjusting for competing risk of death. Cox proportional hazard regression models were used to determine risk factors associated with CAT and the effect of CAT on all-cause mortality. 942 019 patients with cancer were identified; 62 003 (6.6%) had an incident diagnosis of CAT. Patients with pancreatic, brain, ovarian, and lung cancer had the highest, and patients with breast and prostate cancer had the lowest 12-month cumulative incidence of CAT. For most malignancies, men, those with metastatic disease and more comorbidities, and African Americans (vs non-Hispanic Whites) were at highest risk for CAT. Patients diagnosed with cancer between 2014 and 2017 had a higher risk of CAT compared with those diagnosed between 2005 and 2007. CAT was associated with increased overall mortality for all malignancies (HR ranges 1.89 to 4.79). The incidence of CAT increased over time and was driven by an increase in pulmonary embolism±deep vein thrombosis (PE±DVT). CAT incidence varies based on tumor type and stage and on individual risk factors including gender, race/ethnicity, and comorbidities. For all tumor types, CAT is associated with an increased mortality.

1 January 2009 in Cancer Investigation
Verified
Journal Article
Closed access
TWTed Wun
Ted Wun
RWRichard H. White
Richard H. White
Although cancer is recognized as a major risk factor for venous thromboembolism, the exact magnitude of the problem and specific risk factors most strongly associated with the development of VTE is not well defined. Several recent studies have shown that the incidence of VTE is highest in patients who present with metastatic cancer, particularly cancers associated with a high one-year mortality rate, such as pancreatic cancer. The incidence rate of VTE is highest in the first few months after the diagnosis of cancer, and it decreases over time thereafter. For most cancers, it is not clear to what extent undergoing major surgery adds to the already high risk of VTE associated with the presence of the cancer. However, patients with glioma clearly have a very high incidence of VTE soon after they undergo any invasive neurosurgical procedure. Active chemotherapy, the use of erythropoetin agents, and the use of certain anti-cancer therapies such as thalidomide, high-dose steroids, and anti-angiogenic therapy also increase the risk of thrombosis. Similar to patients without cancer, the risk of VTE is higher in patients with coexisting chronic medical illnesses. Development of VTE is clearly associated with decreased survival and this effect is greater among patients initially diagnosed with local or regional stage cancer compared to patients with metastatic cancer.

3 April 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ABAnn Brunson
Ann Brunson
ALAmy Lei
Amy Lei
ARAaron S. Rosenberg
Aaron S. Rosenberg
RWRichard H. White
Richard H. White
TKTheresa Keegan
Theresa Keegan
TWTed Wun
Ted Wun

11 July 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
OAOyebimpe Adesina
Oyebimpe Adesina
ABAnn Brunson
Ann Brunson
TKTheresa H. M. Keegan
Theresa H. M. Keegan
TWTed Wun
Ted Wun
Key Points: In sickle cell disease, ONFH incidence accelerates in early adulthood. Frequent hospitalizations and antecedent acute chest syndrome are independently associated with sickle cell–related ONFH.